State of Wyoming Has $1.16 Million Stake in Globus Medical, Inc. $GMED

State of Wyoming trimmed its position in shares of Globus Medical, Inc. (NYSE:GMED) by 40.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,248 shares of the medical device company’s stock after selling 9,042 shares during the period. State of Wyoming’s holdings in Globus Medical were worth $1,157,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in GMED. AQR Capital Management LLC grew its holdings in shares of Globus Medical by 45.9% during the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock valued at $1,622,000 after buying an additional 7,086 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in Globus Medical by 33.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after acquiring an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Globus Medical by 38.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock valued at $2,228,000 after purchasing an additional 8,540 shares during the period. Jones Financial Companies Lllp lifted its position in shares of Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after purchasing an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after purchasing an additional 28,027 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Price Performance

Shares of NYSE:GMED opened at $77.92 on Thursday. The stock has a market capitalization of $10.58 billion, a P/E ratio of 18.12, a P/E/G ratio of 1.61 and a beta of 0.95. The business has a 50-day moving average of $86.53 and a two-hundred day moving average of $88.30. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the prior year, the firm posted $0.68 EPS. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Analysts Set New Price Targets

GMED has been the subject of a number of research analyst reports. Wells Fargo & Company cut their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Royal Bank Of Canada lifted their price target on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.